Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-ketamine for Cortical Spreading Depolarisation
NCT05095857Phase 4Recruiting
- Sponsor
- Rigshospitalet
- Start
- Sep 2023
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of esketamine in traumatic brain injury (TBI), aneurysmal subarachnoid hemorrhage (SAH) and intracerebral hemorrhage (ICH) (2 arms), sponsored by Rigshospitalet. Primary endpoint: Occurrence of Cortical Spreading Depolarisations after randomisation up to 14 days. Started Sep 2023; status: recruiting.
02
Drugs
esketamine
03
Conditions
traumatic brain injury (TBI)aneurysmal subarachnoid hemorrhage (SAH)intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on NCT05095857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05095857.